New Bladder-Sparing combo could change how we treat aggressive bladder cancer

NCT ID NCT06470282

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for muscle-invasive bladder cancer that aims to save the bladder. It combines two drugs (enfortumab vedotin and pembrolizumab) with targeted radiation. About 47 adults with this cancer will receive the therapy to see if it can shrink tumors and avoid the need for bladder removal. The goal is to achieve a complete response, meaning no cancer is found after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER MUSCLE INVASIVE BLADDER CARCINOMA STAGE II BLADDER CANCER AJCC V8 STAGE IIIA BLADDER CANCER AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact